Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With ...

The greatest disparity in BC-specific survival was observed in women with HR+ HER2− tumors, with Black women having a 50% ...

The FDA has approved Rybrevant in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ...

Despite advancements in early detection and innovative treatments, Black women in the United States face higher mortality ...

HER3 (also known as ERBB3) is a crucial member of the Epidermal Growth Factor Receptor (EGFR) family. It plays a significant role in cellular proliferation, survival, and differentiation via the ...

The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages ...

Results have been positive, with SHR-1701 demonstrating improvements in overall survival, but taking market share will be a ...

Black Diamond Therapeutics, Inc. (BDTX) announced positive initial Phase 2 results for BDTX-1535 in patients with relapsed or ...

Stimulation of epidermal keratinocytes by insulin-like growth factor I (IGF-I ... We hypothesized that inhibition of IGF-I receptor expression in the psoriasis lesion would reverse psoriatic ...

Although endocrine therapy remains the mainstay of treatment for hormone receptor–positive/human epidermal growth factor receptor 2–negative mBC, significant progress has been and continues to be made ...

[10] Epidermal growth factor receptor is a member of the erbB/human epidermal growth factor receptor family of tyrosine kinases, which includes erbB2/HER2, erbB3/ HER3 and erbB4/HER4. Epidermal ...